The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COMMENTARY
COMMENTARY
- Pharma Should Tap Health Coverage Debate as Catalyst to Draw Govt’s Commitment on Innovation
October 1, 2019
- After Death in First-in-Human Study, MHLW Needs to Release Info. to Alleviate Concerns about Participation in Studies
August 26, 2019
- Generic Players Step Up Info Disclosure for Survival in Post-80% Era
July 16, 2019
- Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
July 5, 2019
- Filing for Sakigake Radiation Therapy Expected This Year for Head and Neck Cancer; Expanded Use, Overseas Development Eyed
June 25, 2019
- Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
April 16, 2019
- Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
April 2, 2019
- Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
- Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
February 20, 2019
- 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
- LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
- After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
- Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
November 27, 2018
- There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
- Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
July 12, 2018
- LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications
July 5, 2018
- Kudos to MHLW for Creating New Confab, but 1st Meeting Stirs Industry Frustration
May 30, 2018
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts
April 23, 2018
- With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
April 4, 2018
- Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?
March 12, 2018
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…